Mission statement
RepliBone GmbH is a privately-held Tissue Engineering company, with a mission to develop novel procedures through its technologies for providing autologous ex vivo in vitro expanded hard and soft tissue replications.
Replibone’s technology enables a true and thus revolutionary way of tissue defect filling as it deals with full functional autologous living organoids of genetic identity and differentiation status of the target tissue.
The hard tissue organoids are applicable in tissue repair across a range of clinical indications:
The soft tissue organoids are applicable in organ repair like pancreas, liver, brain, eye, blood vessels and at a later aim heart muscle.
The RepliBone system will provide standardized hard and soft tissue, very much appreciated by the pharmaceutical industry for early drug testing (preclinical) to help to reduce animal trials. This not only for ethical reasons, but using human organ models provides much more meaningful results compared to the animal model.
RepliBone GmbH is a privately-held Tissue Engineering company, with a mission to develop novel procedures through its technologies for providing autologous ex vivo in vitro expanded hard and soft tissue replications.
Replibone’s technology enables a true and thus revolutionary way of tissue defect filling as it deals with full functional autologous living organoids of genetic identity and differentiation status of the target tissue.
The hard tissue organoids are applicable in tissue repair across a range of clinical indications:
- Accident/military injuries „critical size defects“
- Bone volume losses after cancer resections (reconstructive surgery face, spine)
- Bone volume compensations in the field of oral implants
The soft tissue organoids are applicable in organ repair like pancreas, liver, brain, eye, blood vessels and at a later aim heart muscle.
The RepliBone system will provide standardized hard and soft tissue, very much appreciated by the pharmaceutical industry for early drug testing (preclinical) to help to reduce animal trials. This not only for ethical reasons, but using human organ models provides much more meaningful results compared to the animal model.
